Alenfral - General Information
Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Pharmacology of Alenfral
Alenfral is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Alenfral has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ß-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.
Alenfral for patients
Patients should be counseled that antibacterial drugs including Ceclor should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Ceclor is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Ceclor or other antibacterial drugs in the future.
No information provided.
Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
Additional information about Alenfral
Alenfral Indication: For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Mechanism Of Action: Alenfral, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.
Drug Interactions: Probenecid Probenecid increases the antibiotic's level
Food Interactions: Preferably on an empty stomach, not really problematic.
Generic Name: Cefaclor
Synonyms: CCL; Cefaclor anhydrous; Cefaclorum [INN-Latin]; Cephaclor
Drug Category: Anti-Bacterial Agents; Cephalosporins
Drug Type: Small Molecule; Approved
Other Brand Names containing Cefaclor: Alenfral; Alfacet; Alfatil; Ceclor; Ceclor CD; Distaclor; Kefral; Panacef; Panoral; Raniclor;
Absorption: Well absorbed after oral administration, independent of food intake.
Toxicity (Overdose): Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
Protein Binding: 23.5%
Biotransformation: No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).
Half Life: 0.6-0.9 hour
Dosage Forms of Alenfral: Powder, for solution Oral
Powder, for suspension Oral
Chemical IUPAC Name: (6R,7R)-7-[(2-amino-2-phenylacetyl)amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Chemical Formula: C15H14ClN3O4S
Cefaclor on Wikipedia: http://en.wikipedia.org/wiki/Cefaclor
Organisms Affected: Enteric bacteria and other eubacteria